12:00 AM
 | 
Oct 27, 2008
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Carfilzomib: Phase Ib data

Preliminary data from 14 patients in the Phase Ib portion of an open-label, dose-escalation, U.S. Phase Ib/II trial showed that IV carfilzomib was well-tolerated at doses up to 36 mg/m 2 with a low incidence of...

Read the full 157 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >